Literature DB >> 7554806

A survey of beta-lactamase-producing Haemophilus influenzae. An evaluation of 5750 isolates.

S F Rittenhouse1, L A Miller, R L Kaplan, G H Mosely, J A Poupard.   

Abstract

Previous studies have reported that 15%-34% of Haemophilus influenzae produce beta-lactamase. A surveillance program was developed by SmithKline Beecham Clinical Laboratories to determine the current percentage of beta-lactamase-producing H. influenzae from five selected geographic locations in the United States. In 1993, results of 5750 isolates from specimens submitted to five reference clinical laboratories were evaluated. Data were collected from 29 states and the District of Columbia. The percentages of beta-lactamase-producing H. influenzae was 33% and ranged from 22%-40% for the individual states.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7554806     DOI： 10.1016/0732-8893(95)00028-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  8 in total

1.  Identification of beta-lactamase-negative, ampicillin-resistant strains of Haemophilus influenzae with four methods and eight media.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project Beta-Alert 1993-1997.

Authors:  A Derecola; D L Butler; R L Kaplan; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.

Authors:  G V Doern; A B Brueggemann; G Pierce; H P Holley; A Rauch
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.

Authors:  L Zerva; D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1996-08       Impact factor: 5.948

7.  Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).

Authors:  G V Doern; R N Jones; M A Pfaller; K Kugler
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  Yoshiro Morikawa; Miyoshi Kitazato; Junichi Mitsuyama; Shingo Mizunaga; Shinzaburo Minami; Yasuo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.